Allergan and MedImmune enter $1.5bn licensing deal

04-10-2016

Allergan and MedImmune enter $1.5bn licensing deal

360b / Shutterstock.com

Allergan and MedImmune have entered into a $1.52 billion licensing agreement under which Allergan has gained the global rights to develop MEDI2070, which treats inflammatory disorders.


Allergan, MedImmune, AstraZeneca, MEDI2070, biologics, licensing agreement

LSIPR